NCT05797246 2026-04-14
Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
Clinical Trials
41 trialsNCT03911388 2026-04-13
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT04482933 2026-02-10
HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma
Pediatric Brain Tumor Consortium
Phase 2 Withdrawn
NCT04124198 2025-12-31
QoLATI
Rigshospitalet, Denmark
Phase NA Active not recruiting
NCT02048332 2025-12-16
VSTs
Children's Hospital Medical Center, Cincinnati
Phase 1/2 Recruiting
NCT02532452 2025-12-16
Third Party Viral Specific T-cells (VSTs)
Children's Hospital Medical Center, Cincinnati
Phase 2 Recruiting
NCT02062827 2025-10-02
M032-HSV-1
University of Alabama at Birmingham
Phase 1 Active not recruiting
NCT05831111 2025-09-30
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants
ModernaTX, Inc.
Phase 1 Active not recruiting
NCT04013802 2025-08-08
TETRAVI
Baylor College of Medicine
Phase 1 Recruiting
NCT05453006 2025-07-10
Isbaar
University of Minnesota
Phase NA Completed
NCT04772469 2025-04-29
Self-Test Strategies and Linkage Incentives to Improve ART and PrEP Uptake in Men
University of California, San Francisco
Phase NA Completed
NCT04053283 2025-03-24
STAR
Akamis Bio
Phase 1 Completed
NCT03487549 2024-11-27
COVE-1
Verrica Pharmaceuticals Inc.
Phase 2 Completed
NCT03981822 2024-11-27
CARE-1
Verrica Pharmaceuticals Inc.
Phase 2 Completed
NCT03463694 2024-05-17
ELVIS Kids
University of Edinburgh
Phase NA Completed
NCT02457845 2024-01-19
HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors
University of Alabama at Birmingham
Phase 1 Completed
NCT03806764 2023-06-01
CReSCT
Melbourne Health
Phase NA Unknown
NCT03408587 2023-05-06
CLEVER
Viralytics
Phase 1 Completed
NCT02759588 2023-01-05
GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer
Genelux Corporation
Phase 1/2 Completed
NCT03852511 2022-06-24
FORTITUDE
Akamis Bio
Phase 1 Completed
NCT05387226 2022-05-24
Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma
The First Affiliated Hospital of Bengbu Medical University
Phase 1 Unknown
NCT05180851 2022-02-01
YSCH-01
Shanghai Fengxian District Central Hospital
Phase EARLY_PHASE1 Unknown
NCT05066958 2021-10-04
Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 1/2 Unknown
NCT01438112 2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3 Terminated
NCT02482428 2021-01-05
Efficacy and Tolerability of Topical LFX453 for External Genital Warts
Novartis
Phase 2 Completed
NCT02227641 2020-12-14
Preventative/Preemptive Adoptive Transfer of Peptide Stimulated CMV/EBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation
University of Erlangen-Nürnberg Medical School
Phase 1/2 Completed
NCT02868242 2020-03-02
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy
Gilead Sciences
Phase 2 Completed
NCT00423046 2020-01-02
Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age
GlaxoSmithKline
Phase 3 Completed
NCT01136395 2019-10-08
Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation
University of Giessen
Phase 2 Completed
NCT01570283 2019-05-30
ARMS
AlloVir
Phase 1/2 Completed
NCT03818334 2019-02-01
Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies
Hospital Israelita Albert Einstein
Phase 2/3 Recruiting
NCT00492544 2018-09-04
Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age
GlaxoSmithKline
Phase 3 Completed
NCT00541970 2018-08-17
Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs
GlaxoSmithKline
Phase 1 Completed
NCT02724254 2018-07-20
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients
Vaxart
Phase 2 Completed
NCT01804829 2017-03-15
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
Biotest Pharmaceuticals Corporation
Phase 3 Completed
NCT01528865 2016-03-11
Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma
University of Michigan Rogel Cancer Center
Phase 1/2 Withdrawn
NCT00574977 2015-12-28
Safety Study of Modified Vaccinia Virus to Cancer
University of Pittsburgh
Phase 1 Completed
NCT00952185 2015-06-08
Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers
City of Hope Medical Center
Phase NA Terminated
NCT01070797 2014-09-04
VIRAGE
Baylor College of Medicine
Phase 1 Completed
NCT00925288 2012-10-11
Girasol
Johns Hopkins Bloomberg School of Public Health
Phase 4 Completed
NCT01031719 2012-09-13
Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors
Chiltern Pesquisa Clinica Ltda
Phase 3 Completed